Cardiol Therapeutics(CRDL-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low1.0400
Day High1.0900
Open:1.0400
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Tipranks
Cardiol Therapeutics Shareholders Back Board Slate and Auditor at 2026 AGM
Newswire.ca
Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders
Tipranks
Cardiol Therapeutics to Webcast June 24 Virtual AGM as Late-Stage Cardiac Programs Advance
Newswire.ca
Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT
Tipranks
H.C. Wainwright Keeps Their Buy Rating on Cardiol Therapeutics (CRDL)
Tipranks
Cardiol Therapeutics Sets June 24, 2026 Virtual AGM and Adopts Notice-and-Access for Proxy Materials
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Pharvaris (PHVS), Cardiol Therapeutics (CRDL)
Tipranks
Cardiol Therapeutics to Present Pipeline at H.C. Wainwright BioConnect Conference at NASDAQ
Newswire.ca
Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ
Tipranks
Analysts Offer Insights on Healthcare Companies: Cardiol Therapeutics (CRDL) and BridgeBio Pharma (BBIO)
Tipranks
Cardiol Therapeutics Reports Higher Q1 2026 Loss but Stronger Cash Position
Tipranks
Cardiol Therapeutics’ Phase II MAvERIC Pericarditis Data Accepted by JAHA as Phase III Trial Nears Completion
Newswire.ca
Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association
Newswire.ca
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program
Tipranks
Cardiol Therapeutics Showcases MAVERIC Phase III Trial and ARCHER Results in Barchart Live Interview
Newsfile
Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart
Tipranks
Cardiol Therapeutics Sets June 24, 2026 Date for Annual General Meeting of Shareholders
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Tipranks
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Alzamend Neuro (ALZN) and Cardiol Therapeutics (CRDL)

Profile

Cardiol Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease. The company's lead product consist CardiolRx(TM). Cardiol Therapeutics Inc. is based in Oakville, ON.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.